Form 4: Atossa Therapeutics CFO Heather Rees Acquires Stock Options
SEC Form 4 Filing
Heather Rees, CFO of Atossa Therapeutics, was granted stock options to purchase 543,785 shares of common stock at an exercise price of $0.99 on May 15, 2025.
Summary
- On May 15, 2025, Heather Rees, the Chief Financial Officer of Atossa Therapeutics, Inc., was granted stock options.
- These options allow her to purchase 543,785 shares of Atossa's common stock.
- The exercise price for these options is $0.99 per share, which was the closing stock price on the grant date.
- The options vest quarterly over a 24-month period, contingent upon Ms. Rees's continued service to Atossa Therapeutics.
- The options expire on May 15, 2035.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and indicates confidence in the company's future, but it's not a major event.
Positives
- The granting of stock options to the CFO aligns her interests with those of the shareholders.
- The vesting schedule incentivizes continued service and commitment to the company.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the options.
Industry Context
Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders. This grant is consistent with standard practices.
Comparison to Industry Standards
- Stock option grants are a typical component of executive compensation packages in the biotech industry.
- Companies like Amgen, Gilead, and Biogen also use stock options to incentivize their executives.
- The vesting schedule of 24 months is fairly standard, aligning with industry norms for retaining key personnel.
- The exercise price being set at the closing stock price on the grant date is also a common practice.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive sign, aligning management's interests with the company's performance.
- Employees may see this as a sign of stability and investment in the leadership team.
Key Dates
| Date | Description |
|---|---|
| 05/15/2025 | Date of the stock option grant and earliest transaction date; options vest quarterly over 24 months from this date; exercise price set at $0.99, the closing stock price on this date. |
| 05/16/2025 | Date of signature for the Form 4 filing. |
| 05/15/2035 | Expiration date of the stock options. |
Keywords
stock options, Atossa Therapeutics, Heather Rees, CFO, equity, Form 4, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.